Amplify Weight Loss Drug & Treatment ETF (THNR)
| Assets | $3.94M |
| Expense Ratio | 0.59% |
| PE Ratio | 20.89 |
| Shares Out | 150,000 |
| Dividend (ttm) | $0.41 |
| Dividend Yield | 1.57% |
| Ex-Dividend Date | Dec 30, 2025 |
| Payout Frequency | Annual |
| Payout Ratio | 32.94% |
| Volume | 7,285 |
| Open | 26.26 |
| Previous Close | 26.20 |
| Day's Range | 26.25 - 26.37 |
| 52-Week Low | 18.56 |
| 52-Week High | 27.28 |
| Beta | n/a |
| Holdings | 22 |
| Inception Date | May 21, 2024 |
About THNR
Fund Home PageThe Amplify Weight Loss Drug & Treatment ETF (THNR) is an exchange-traded fund that mostly invests in health care equity. The fund tracks a modified market cap-weighted index of companies from developed markets that manufacture and enable GLP-1 agonist pharmaceutical businesses. THNR was launched on May 21, 2024 and is issued by Amplify Investments.
Top 10 Holdings
71.13% of assets| Name | Symbol | Weight |
|---|---|---|
| Novo Nordisk A/S | NVO | 13.98% |
| Eli Lilly and Company | LLY | 11.94% |
| Amgen Inc. | AMGN | 6.82% |
| Chugai Pharmaceutical Co., Ltd. | 4519 | 6.35% |
| Regeneron Pharmaceuticals, Inc. | REGN | 6.32% |
| Shionogi & Co., Ltd. | 4507 | 5.54% |
| Roche Holding AG | ROG | 5.34% |
| Merck & Co., Inc. | MRK | 5.18% |
| AstraZeneca PLC | AZN | 4.85% |
| Pfizer Inc. | PFE | 4.80% |
Dividend History
| Ex-Dividend | Amount | Pay Date |
|---|---|---|
| Dec 30, 2025 | $0.41317 | Dec 31, 2025 |
| Dec 30, 2024 | $0.2199 | Dec 31, 2024 |
Performance
THNR had a total return of 15.86% in the past year, including dividends. Since the fund's inception, the average annual return has been 3.71%.
News
OZEM Vs. THNR: Which Is The Better ETF In The GLP-1 And Weight Loss Space?
I recommend buying the Roundhill GLP-1 & Weight Loss ETF (OZEM) for strategic exposure to the weight loss drug sector. OZEM offers diversified access to leading GLP-1 innovators like Novo Nordisk and ...
New Year, New Strategy: Navigating Weight Loss ETFs
With the start of 2026, the annual focus on weight loss resolutions presents a timely opportunity for financial advisors to discuss the investment potential of GLP-1 agonists with their clients. This ...
Hims & Hers, Eli Lilly, Novo Nordisk Face FDA Scrutiny: What It Means For Weight-Loss ETFs
The U.S. Food and Drug Administration's recent enforcement action against drug promotion is sending ETFs with exposure to weight-loss treatment manufacturers into question.
SILJ, HACK, THNR: Trends in Thematic Investing
Amplify Junior Silver Miners ETF (SILJ) is up 28% year-to-date. Christian Magoon discusses the outlook for cybersecurity stocks, as Amplify's Cybersecurity ETF (HACK) is up 8% year-to-date.
Why Investors Haven't Feasted on Two New Weight-Loss ETFs
Two new weight-loss exchange-traded funds (ETFs) launched in May have yet to whet investors' appetite, possibly due to their expensive fees and concentrated bets.